Should Labcorp Stock Holders Look At Quest Diagnostics Instead?

Labcorp (LH) and Quest Diagnostics (DGX) both provide lab tests, but differ in additional services. Labcorp raised 2026 revenue guidance for its drug-development labs, while Quest increased its forecast due to testing volume growth. Both face Medicare fee cuts in 2027. Quest trades at lower trailing earnings multiple, grows faster, and has wider margins, but Labcorp is cheaper on sales and adjusted forecast earnings.

Original reporting
Published Nov 13, 2026, 5:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Should Labcorp Stock Holders Look At Quest Diagnostics Instead? — source image
Decision brief

The 30-second read

$LHBullishLow
01

Why it matters

Both tickers are discussed through segment-specific guidance revisions, valuation multiples, and growth/margin comparisons, with Quest also disclosing unauthorized access to a test ordering system and compromised patient data.

02

Market read

Useful for positioning between LH and DGX based on which guidance drivers look more durable, but it is not a fresh disclosure beyond the already-reported October updates.

03

What to watch

Cybersecurity impact on Quest is mentioned but not quantified; traders may need to assess customer retention, regulatory exposure, and remediation costs beyond the article’s qualitative note.

Relevance 4/10Novelty 3/10Timing: post-October guidance comparison, no new scheduled print or event today

Background

The article contrasts Labcorp’s and Quest Diagnostics’ October 2026 guidance updates, focusing on different business mixes and shared Medicare PAMA fee-cut risk.

Company-level read

Ticker impact

$LHBullishMedium confidence
Context

Labcorp raised 2026 outlook on Oct. 28, with Biopharma Laboratory Services revenue midpoint growth lifted to 7.9% and diagnostics up only 20 bps.

Expected impact

Likely mild upward bias as investors reprice the drug-development labs growth versus the smaller diagnostics revision.

Evidence & confidence

The article provides specific, company-attributed guidance changes and segment mix details, but it is framed as a comparison rather than a fresh catalyst beyond the already-reported October updates.

$DGXBullishMedium confidence
Context

Quest raised 2026 revenue growth expectations on Oct. 22 to 9.5% at the midpoint, citing testing volume up 14.5% with new Corewell Health and Fresenius relationships.

Expected impact

Likely upward bias as the market favors the higher-growth, margin-accretive consumer health trajectory despite the PAMA fee cut risk.

Evidence & confidence

The piece includes concrete guidance and volume drivers plus a disclosed cybersecurity incident, but it does not provide a new post-October development that would force an immediate repricing today.

Market effects

Reinforces the lab-services sector’s key debate: growth mix (drug-development labs and consumer health) versus Medicare PAMA fee pressure starting 2027.

Primarily US-listed healthcare services sentiment, with read-through to managed care and hospital testing demand expectations.

Limited, as the drivers cited are US Medicare reimbursement and US partner-driven testing volumes.

Counterpoint

The comparison may overemphasize segment growth while underweighting the 2027 Medicare lab-fee hit and potential reimbursement uncertainty that could compress both companies’ margins.

Key entities

  • Labcorp

    Raised 2026 outlook on Oct. 28, with Biopharma Laboratory Services midpoint growth guided to 7.9% and diagnostics up only 20 bps.

  • Quest Diagnostics

    Raised 2026 revenue growth on Oct. 22 to 9.5% at the midpoint, citing testing volume up 14.5% and partner-driven growth; disclosed unauthorized access to a test ordering system.

  • Corewell Health

    Named as a new relationship contributing to Quest’s testing volume growth.

  • Fresenius Medical Care

    Named as a new relationship contributing to Quest’s testing volume growth.

  • Medicare PAMA

    Proposed changes to Medicare lab fees starting 2027, cited as a shared headwind for both companies.

Related articles

$LHHighAI 9/10

Labcorp completes $375M Millennium Health takeover

Labcorp completed its $375M acquisition of Millennium Health, including $245M upfront and up to $130M in milestone payments. The deal aims to enhance Labcorp's toxicology services and expand its geographic reach. Millennium specializes in drug testing, complementing Labcorp's existing offerings. Labcorp CEO Adam Schechter highlighted the strategic fit and growth potential during an earnings call.

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.